Bank of New York Mellon Corp Sells 24,760 Shares of Cencora, Inc. $COR

Posted by Stanley Muller on Jul 18th, 2026

Bank of New York Mellon Corp decreased its holdings in shares of Cencora, Inc. (NYSE:COR – Free Report) by 2.4% during the first quarter, HoldingsChannel reports. The institutional investor owned 1,028,152 shares of the company’s stock after selling 24,760 shares during the period. Bank of New York Mellon Corp’s holdings in Cencora were worth $322,984,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in COR. Kemnay Advisory Services Inc. purchased a new position in shares of Cencora in the 4th quarter worth approximately $25,000. Oakworth Capital Inc. purchased a new position in Cencora during the 4th quarter worth approximately $26,000. Elyxium Wealth LLC acquired a new position in Cencora during the fourth quarter valued at $27,000. Archer Investment Corp boosted its stake in shares of Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after buying an additional 47 shares during the last quarter. Finally, Motiv8 Investments LLC purchased a new position in shares of Cencora during the 4th quarter valued at approximately $29,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Trading Down 0.1%

Shares of Cencora stock opened at $307.72 on Friday. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. The business’s fifty day moving average is $279.98 and its two-hundred day moving average is $317.68. The firm has a market cap of $59.87 billion, a PE ratio of 23.60, a P/E/G ratio of 1.71 and a beta of 0.58.

Cencora (NYSE:COR – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The firm had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. During the same period last year, the business earned $4.42 EPS. The firm’s revenue was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Analysts anticipate that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora announced that its board has initiated a stock buyback program on Thursday, May 21st that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to repurchase up to 3.9% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s dividend payout ratio (DPR) is presently 18.40%.

Insider Buying and Selling

In related news, Director Lauren M. Tyler bought 550 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were acquired at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the acquisition, the director directly owned 4,359 shares of the company’s stock, valued at $1,177,932.57. The trade was a 14.44% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.38% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Weiss Ratings downgraded Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, June 30th. Wells Fargo & Company dropped their price objective on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research report on Monday, May 11th. William Blair initiated coverage on Cencora in a research report on Tuesday, April 28th. They set a “market perform” rating on the stock. Bank of America increased their price target on shares of Cencora from $280.00 to $285.00 and gave the stock a “neutral” rating in a research note on Wednesday, June 24th. Finally, Robert W. Baird reduced their target price on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $367.75.

Get Our Latest Analysis on COR

Cencora Profile

(Free Report)

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.